Investor Alerts: Key Deadlines for Rocket Pharmaceuticals and Vestis Corporation
New York, Monday, 14 July 2025.
Investors in Rocket Pharmaceuticals and Vestis Corporation must act before August deadlines due to shareholder alerts prompted by litigation over alleged securities violations.
Rocket Pharmaceuticals Faces Litigation
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) investors are being alerted to upcoming deadlines concerning a class action lawsuit alleging securities fraud. The lawsuit, filed in the United States District Court for the District of New Jersey, covers investors who acquired Rocket securities between February 27, 2025, and May 26, 2025. The case contends that Rocket made misleading statements about the safety and clinical trial protocol of its RP-A501 drug, specifically failing to disclose that Serious Adverse Events (SAEs), including death, were a risk [1][3][4][5].
Impact of Allegations on Rocket Pharmaceuticals
These allegations have had significant repercussions on Rocket Pharmaceuticals’ stock price, which fell approximately 37% from $6.27 per share on May 23, 2025, to $2.33 per share by May 27, 2025, following the announcement of a clinical hold by the FDA due to a patient death in the trial [3][5]. Investors who have been financially impacted have until August 11, 2025, to apply for lead plaintiff status [1][5].
Emerging Developments in Vestis Corporation Case
Vestis Corporation (NYSE: VSTS) is similarly under scrutiny as a class action lawsuit was filed in the United States District Court for the Southern District of New York. The lawsuit addresses alleged misrepresentations from the company regarding its business growth capabilities. Investors who purchased Vestis shares between May 2, 2024, and May 6, 2025, are included in this class action, with a lead plaintiff filing deadline of August 8, 2025 [2].
Legal Context and Investor Actions
Both cases illustrate the increasing regulatory oversight in corporate communications and the necessity for companies to maintain transparency with their shareholders. Investors are urged to stay informed about these legal processes, which could significantly affect their investment outcomes. Bernstein Liebhard LLP, representing the investors in both class actions, emphasizes the importance of understanding shareholder rights and potential recovery options [1][2][4].